TWI339582B - Use of alkylphosphocholines in the preventive application of protozoal diseases - Google Patents

Use of alkylphosphocholines in the preventive application of protozoal diseases

Info

Publication number
TWI339582B
TWI339582B TW092100614A TW92100614A TWI339582B TW I339582 B TWI339582 B TW I339582B TW 092100614 A TW092100614 A TW 092100614A TW 92100614 A TW92100614 A TW 92100614A TW I339582 B TWI339582 B TW I339582B
Authority
TW
Taiwan
Prior art keywords
alkylphosphocholines
protozoal diseases
preventive application
preventive
application
Prior art date
Application number
TW092100614A
Other languages
Chinese (zh)
Other versions
TW200302103A (en
Inventor
Jurgen Engel
Original Assignee
Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris Gmbh filed Critical Zentaris Gmbh
Publication of TW200302103A publication Critical patent/TW200302103A/en
Application granted granted Critical
Publication of TWI339582B publication Critical patent/TWI339582B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW092100614A 2002-01-25 2003-01-13 Use of alkylphosphocholines in the preventive application of protozoal diseases TWI339582B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10203195A DE10203195A1 (en) 2002-01-25 2002-01-25 Use of alkylphosphocholines in the preventive treatment of protozoal diseases

Publications (2)

Publication Number Publication Date
TW200302103A TW200302103A (en) 2003-08-01
TWI339582B true TWI339582B (en) 2011-04-01

Family

ID=7713213

Family Applications (1)

Application Number Title Priority Date Filing Date
TW092100614A TWI339582B (en) 2002-01-25 2003-01-13 Use of alkylphosphocholines in the preventive application of protozoal diseases

Country Status (16)

Country Link
EP (1) EP1467742A1 (en)
JP (1) JP2005515244A (en)
CN (1) CN1622811A (en)
AR (1) AR038224A1 (en)
AU (1) AU2003236787B2 (en)
BR (1) BR0307021A (en)
CA (1) CA2470185A1 (en)
CO (1) CO5601024A2 (en)
DE (1) DE10203195A1 (en)
IL (2) IL162492A0 (en)
MX (1) MXPA04007193A (en)
NZ (1) NZ548040A (en)
PE (1) PE20030732A1 (en)
TW (1) TWI339582B (en)
WO (1) WO2003061669A1 (en)
ZA (1) ZA200404690B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT501545B1 (en) * 2005-02-23 2007-10-15 Obwaller Andreas Dr CLEANING AGENT FOR CONTACT LENSES
AR058397A1 (en) * 2005-12-19 2008-01-30 Zentaris Gmbh DERIVATIVES OF ALQUILFOSFOLIPIDOS WITH REDUCED CYTOTOXICITY AND USES OF THE SAME
EP1800684A1 (en) * 2005-12-20 2007-06-27 Zentaris GmbH Novel alkyl phospholipid derivatives and uses thereof
CN104473941A (en) * 2014-12-20 2015-04-01 长沙佰顺生物科技有限公司 Miltefosine-containing medicine preparation and preparation method thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4132345A1 (en) * 1991-09-27 1993-04-01 Max Planck Gesellschaft Medicament compsns. for intravenous admin. of lytic agents - used for treatment of tumours, auto-immune disorders, multiple sclerosis, etc.
DE4132344A1 (en) * 1991-09-27 1993-04-01 Max Planck Gesellschaft METHOD FOR PRODUCING A MEDAL FOR ORAL OR TOPICAL ADMINISTRATION IN THE TREATMENT OF LEISHMANIASIS
CA2131024A1 (en) * 1992-03-06 1993-09-16 Arsalan Kharazmi Treatment and prophylaxis of diseases caused by parasites, or bacteria
HUP0004363A3 (en) * 1998-01-22 2002-12-28 Zentaris Gmbh Solid pharmaceutical compositions containing miltefosine for use in the treatment of leishmaniasis
DE10020812C2 (en) * 2000-04-20 2003-06-26 Robert Koch Inst Use of naphthindazole-4,9-quinones as antiparasitic agents
AU2002232400A1 (en) * 2000-11-06 2002-05-15 U.S. Army Medical Research And Materiel Command Reversed amidines and methods of using for treating, preventing, or inhibiting leishmaniasis

Also Published As

Publication number Publication date
AU2003236787B2 (en) 2007-03-22
CO5601024A2 (en) 2006-01-31
TW200302103A (en) 2003-08-01
EP1467742A1 (en) 2004-10-20
WO2003061669A1 (en) 2003-07-31
NZ548040A (en) 2007-06-29
JP2005515244A (en) 2005-05-26
PE20030732A1 (en) 2003-09-27
AR038224A1 (en) 2005-01-05
IL162492A0 (en) 2005-11-20
CN1622811A (en) 2005-06-01
IL162492A (en) 2009-12-24
BR0307021A (en) 2004-11-03
CA2470185A1 (en) 2003-07-31
ZA200404690B (en) 2004-09-27
MXPA04007193A (en) 2004-10-29
DE10203195A1 (en) 2003-08-07

Similar Documents

Publication Publication Date Title
AU2003216482A8 (en) Msras as modifiers of the p53 pathway and methods of use
HRP20040906B1 (en) Bisphosphonic acid for the treatment and prevention of ostreoporosis
PT1583542E (en) Compositions and methods for combination antiviral therapy
EP1572890A4 (en) Slc7s as modifies of the p53 pathway and methods of use
HK1073997A1 (en) Administration of agents for the treatment of inflammation
EP1578367A4 (en) Compositions and methods for the treatment of immune related diseases
EP1572116A4 (en) Compositions and methods for the treatment of immune related diseases
EP1576137A4 (en) Compositions and methods for the treatment of immune related diseases
PL374118A1 (en) Interleukin-1 receptors in the treatment of diseases
HK1061212A1 (en) Pyranoindazoles and their use for the treatment ofglaucoma
EP1520043A4 (en) METHODS FOR THE IDENTIFICATION OF IKKa FUNCTION AND OTHER GEN ES USEFUL FOR TREATMENT OF INFLAMMATORY DISEASES
PL371281A1 (en) Methods and compositions for the treatment of eye diseases
AU2003215257A8 (en) Modified defensins and their use
GB0213869D0 (en) The treatment of pain
GB0207411D0 (en) Azole compounds and their therapeutic use
HK1080370A1 (en) Bisphosphonates for the treatment of atherosclerosis and devices comprising them
GB0207410D0 (en) Compounds and their therapeutic use
TWI339582B (en) Use of alkylphosphocholines in the preventive application of protozoal diseases
LT1496918T (en) Use of sodium meta-arsenite for the treatment of tumours
GB0201025D0 (en) The treatment of degenerative diseases
AU2003205963A8 (en) Azaphenylalanine derivatives and their use as antithrombotic agents
IL164951A0 (en) The treatment of pain with lfendropil
EP1488800A4 (en) Agent for the treatment of protozoal diseases
AU2003236787A1 (en) Use of alkylphosphocholines for the preventative treatment of protozoan diseases
GB0207409D0 (en) Benzofuran-2H-3-one compounds and their therapeutic use

Legal Events

Date Code Title Description
MK4A Expiration of patent term of an invention patent